A Closer Look at 9 Analyst Recommendations For Johnson & Johnson
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Johnson & Johnson (NYSE:JNJ) show a predominantly somewhat bullish outlook, with 8 out of 9 analysts giving such ratings in the last three months. The average 12-month price target for JNJ has been raised to $202.33, marking a 19.02% increase from the previous target of $170.00. This adjustment reflects a positive sentiment towards JNJ's market performance, driven by its strong financial indicators such as revenue growth, net margin, ROE, and ROA. The company's strategic focus areas include immunology, oncology, neurology, and cardiology, with significant contributions from its pharmaceutical and medical devices divisions.
April 15, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's stock may see a positive short-term impact due to the recent analyst ratings upgrade and the significant increase in the 12-month price target. The company's strong financial performance and strategic focus on high-growth areas are likely to bolster investor confidence.
The positive shift in analyst ratings, especially the increase in the 12-month price target, reflects a strong bullish sentiment towards JNJ. This is further supported by the company's impressive financial performance, including revenue growth, high net margin, and strong ROE and ROA. Given these factors, JNJ's stock is likely to experience upward momentum in the short term as these updates align with investor interests in growth and stability.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100